Ritter Pharmaceuticals Regains Compliance with Nasdaq’s Stockholders’ Equity Requirement for Continued Listing
May 11, 2020 08:00 ET
|
Ritter Pharmaceuticals, Inc.
LOS ANGELES, May 11, 2020 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), today announced that it has received written notice from the...
Ritter Pharmaceuticals Reports Financial Results for the First Quarter Ended March 31, 2020
May 01, 2020 17:34 ET
|
Ritter Pharmaceuticals, Inc.
LOS ANGELES, May 01, 2020 (GLOBE NEWSWIRE) -- Form S-4 Declared Effective by the SEC and Ritter/Qualigen Merger Voting is Underway Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter...
Ritter Pharmaceuticals, Inc. Urges Stockholders to Vote Now on Proposed Merger with Biotech Company, Qualigen Inc.
April 28, 2020 07:30 ET
|
Ritter Pharmaceuticals, Inc.
The merger CANNOT be consummated without the approval of EACH of the proposals being voted on at the Special Meeting, including approval of a reverse stock split. LOS ANGELES, April 28, 2020 ...
Ritter Pharmaceuticals Appoints Esteemed Gastroenterologist Anthony J. Lembo, M.D. to its Medical Advisory Board
August 13, 2019 09:15 ET
|
Ritter Pharmaceuticals, Inc.
LOS ANGELES, Aug. 13, 2019 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that modulate...
Ritter Pharmaceuticals Hosts Conference Call on August 7, 2019 to Highlight Recent Lactose Intolerance Market Research Findings
July 31, 2019 09:00 ET
|
Ritter Pharmaceuticals, Inc.
Daniel P. Lundberg, Consultant to Ritter Pharmaceuticals and former Senior VP of Marketing at Salix Pharmaceuticals to address market opportunity for Phase 3, lactose intolerance drug candidate RP-G28...
Ritter Pharmaceuticals Announces Last Patient Last Visit in its Phase 3 “Liberatus” Clinical Trial of RP-G28 for Lactose Intolerance
July 02, 2019 09:00 ET
|
Ritter Pharmaceuticals, Inc.
Top-line Data Readout Remains on Track for early Q4 2019 LOS ANGELES, July 02, 2019 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a...
Ritter Pharmaceuticals Shares New Market Research Illuminating the Life Challenges of a Lactose Intolerance Sufferer
May 30, 2019 07:00 ET
|
Ritter Pharmaceuticals, Inc.
Current treatment options only provide full symptom relief to 9% of patients; 90% of sufferers want a better solution LOS ANGELES, May 30, 2019 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc....
Ritter Pharmaceuticals to Host Expert Call with Dr. William Chey on February 20, 2019
February 12, 2019 08:30 ET
|
Ritter Pharmaceuticals, Inc.
Leading Gastrointestinal Disease Expert to Address Unmet Medical Need in Lactose Intolerance and the Potential of Phase 3 Drug Candidate RP-G28 LOS ANGELES, Feb. 12, 2019 (GLOBE NEWSWIRE) -- ...
Ritter Pharmaceuticals Reaches Halfway Mark for Enrollment in Pivotal Phase 3 Clinical Trial of RP-G28 in Patients with Lactose Intolerance
December 04, 2018 08:30 ET
|
Ritter Pharmaceuticals, Inc.
Full Enrollment on Target for Q2 2019 with Data Readout Expected in the Second Half of 2019 LOS ANGELES, Dec. 04, 2018 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter...